Prior COVID-19 infection was not independently associated with an increased risk for upper respiratory tract infections in adults.

Nirmatrelvir-ritonavir reduced the risk for long COVID in adults aged 50 years and older but not in adolescents.

Among ICU patients with cirrhosis and sepsis, a high lactate-to-hematocrit ratio predicted short- and long-term mortality.

Asthma clinical remission among patients taking dupilumab is most likely to occur in those with increased baseline BEC and FeNO levels.

Adding paridiprubart to standard care in ICU patients with COVID respiratory distress may reduce invasive support needs and allow earlier discharge.

Tirzepatide treatment may lead to OSA remission or mild nonsymptomatic OSA in patients with moderate to severe OSA and obesity.